AGP Executive Report

Wound Care Innovation: AGC Biologics will manufacture a new recombinant wound-and-skin healing product for Flen Health, scaling lactoperoxidase and glucose oxidase production for GMP and Phase II trials. Women’s Health & Safety: A large Danish BMJ study finds current oral menopausal hormone therapy raises blood-clot risk, while transdermal therapy shows no general increase; separate reporting highlights endometriosis patients pushing for better treatment outcome tracking after a petition was dropped. Obesity Drug Watch: Sweden reports rising semaglutide side-effect complaints, with many eye-related cases and only one NAION reimbursement so far. Healthcare Workforce: Novo Nordisk says it has cut about 13,000 jobs as it reshapes for the next phase of obesity-drug competition. Vision Technology: Aarhus-led research describes light-sensitive nanoparticles that could activate degenerating retinal cells, pointing toward a new retinal prosthesis approach. Public Health Research: Danish-led work also links Campylobacter coli clusters across multiple European countries, including Denmark, challenging assumptions about sporadic spread. Policy & Care Access: Denmark and Thailand explored healthy ageing cooperation, including traditional Thai massage, at a Copenhagen event.

HRT Safety Update: A large Danish registry study in BMJ warns that oral hormone replacement therapy can raise the risk of serious blood clots, heart attack and stroke—while transdermal options (patches, gels, sprays) appear safer. Clinical Research: Danish company Breye Therapeutics says an academic paper in Science Translational Medicine supports its oral danegaptide approach for earlier, non-invasive treatment of non-proliferative diabetic retinopathy, with a Phase II trial planned. Cardiac Care & Patient Choice: Christian Eriksen and VfL Wolfsburg have mutually agreed to end his contract early so he can continue rehabilitation close to family in Denmark after his on-field collapses. Pharma Markets: Novo Nordisk CEO Mike Doustdar says a direct NYSE share listing is on the table, potentially replacing ADR trading as investors focus on growth and pipeline. Public Health Debate: A major review finds no strong causal link between prenatal paracetamol (Tylenol) exposure and autism/ADHD, weakening earlier concerns. Health Policy & Prevention: Denmark’s co-housing model is highlighted as a way to reduce isolation for older LGBTQ+ adults, with calls for more culturally competent care.

Uterine Cancer & Drinking Water: A large California study links higher exposure to regulated drinking-water contaminants (trihalomethanes and haloacetic acids) with increased uterine cancer risk, raising questions about whether current limits are protective. Birth Injury & Infection Prevention: Denmark’s REPAIR trial analysis finds long pushing stages and deep second-degree tears raise clinically relevant wound complications after vaginal delivery, while preventive antibiotics were linked to lower odds. Ageing & Muscle Strength: New research points to a breakdown in nerve-to-muscle communication driving sarcopenia, and identifies a protein that could be targeted to preserve strength in older adults. Type 2 Diabetes & Cancer Risk: Danish data show people with type 2 diabetes face higher cancer incidence, with women particularly affected, especially for obesity-related cancers. Novo Nordisk Strategy Watch: Novo’s Capital Markets Day update includes further job cuts and plans to expand oral GLP-1 manufacturing capacity, but investors reacted coolly, sending shares down. GLP-1 Thyroid Warning Clarified: A report explains the FDA boxed warning applies mainly to medullary thyroid cancer/MEN2, not the most common thyroid cancers. Denmark in Global Care: A Danish delegation visited Seoul Seobuk Hospital to study dementia care, TB control and palliative approaches in a public hospital setting. EU Sport & Activity: A Eurobarometer survey finds more Europeans are exercising than in 2022, with Denmark and Finland leading daily activity.

GLP-1 Vision Loss Lawsuits: In the US, dozens of people have sued makers of Wegovy and Ozempic over alleged links to NAION, a rare but often permanent optic nerve condition; researchers cite a Danish cohort signal (higher incidence with semaglutide, though not proof of causation) and note absolute risk appears low, while regulators review safety. Breast Cancer Screening: A new reanalysis of randomized mammography trials suggests overdiagnosis may be lower than earlier estimates, aligning with Danish screening patterns. Blood Pressure Focus: Danish-led research reports that systolic readings matter most overall, but diastolic and combined measures may be especially informative for people under 50. Gestational Diabetes to Type 2: Using Danish DD2 data, clinicians report women with gestational diabetes develop type 2 diabetes much earlier (median 43.5 vs 56.3 years). Novo Strategy & Pipeline: Novo Nordisk unveiled plans to scale oral obesity manufacturing and expand its blockbuster pipeline, as investors react to growth expectations. Energy Drinks in the Nordics: Nordic researchers warn of high daily use among Swedish teens and report notable negative health effects and dependency concerns.

Childhood obesity push: Novo Nordisk and UNICEF are expanding a programme to prevent childhood overweight and obesity, adding $18m (2026–2030) to reach 80m+ children across Mexico, Colombia, Indonesia, the Philippines, India, Egypt and Kenya, with nutrition and physical activity counselling plus basic mental health screening. Novo investor jitters: Shares in Novo slid about 7.7% after a new strategy at Capital Markets Day, as investors questioned concrete growth targets and the weight-loss outlook; the plan aims for 5+ “multi-blockbusters” by 2030 and DKr150bn+ sales by 2035. Breast screening reassurance: A Danish-led reanalysis suggests overdiagnosis in breast cancer screening is lower than previously feared, with excess cases matching expectations and estimated overdiagnosis below 5% in Denmark. Nordic health warning: Nordic officials warn energy drinks are becoming a daily habit for many young people, with Finland seeing the earliest starts (before age 12 for one in four). EU Kids Act: The EU proposes tighter rules for child social media use, including a ban for under-13s and limits on addictive design features. Local health service: A community prostate cancer screening in Stamford offered PSA blood tests to 100 men, aiming for earlier detection and better treatment options.

GLP-1 Vision Lawsuits: More patients are suing Eli Lilly and Novo Nordisk over claims that weight-loss drugs like Ozempic and Zepbound can cause permanent blindness via NAION, with thousands of cases now consolidated in U.S. courts. Novo’s Next-Gen Obesity Bet: Novo says its CagriSema trial showed ~12.4% average weight loss in diabetes patients, aiming to challenge Lilly ahead of Wegovy patent expiries. Type 2 Diabetes–Cancer Link: Danish researchers report type 2 diabetes raises cancer risk—women +22% and men +12%—with higher danger for obesity-related cancers. Denmark in EU Digital Health: The EU highlights eDelivery as open-source-friendly infrastructure for interoperable services; Denmark is cited for healthcare messaging use. EU Privacy Crackdown: Ireland’s regulator fined Google €403m for improper handling of EU users’ location data under GDPR. Arctic Security Deal: Denmark says NATO shares responsibility for Arctic security under a Greenland agreement with the U.S., with a new base reopening planned. Workforce Planning: Germany published a health-sector shortage list for EU Blue Card eligibility, naming 12 qualifying medical and nursing roles.

Brain-Tech Breakthrough: DTU and partners (incl. University of Copenhagen) unveiled a needle-thin microfluidic brain implant that can record neural activity and deliver medication to precise spots—aimed first at epilepsy and brain research, with longer-term therapeutic potential. Cancer & Nutrition: Denmark-led EVITA trial results suggest daily 1,000 mg vitamin C may improve outcomes for people with pre-cancerous blood disorders/early blood cancers by shifting inflammatory signals and reducing some adverse events, though it didn’t clearly change abnormal cell growth rates. GLP-1 Safety Watch: New reports and lawsuits highlight rare but serious permanent vision loss linked to long-term GLP-1 use, with calls for eye checks when starting treatment. Novo Nordisk Update: Novo’s Capital Markets Day targets 5+ blockbuster launches by 2030 and >150 bn DKK pipeline sales by 2035, but shares fell as analysts questioned pricing power; the company also said it has cut 13,000 jobs total. Mental Health Trends: A Danish study in JAMA Psychiatry finds today’s ADHD/autism diagnoses increasingly resemble the general population, suggesting changing risk profiles and/or detection patterns.

GLP-1 Safety Alarm: A new wave of lawsuits and reports links long-term Ozempic/Wegovy/Mounjaro use to rare but permanent vision loss, with doctors urging eye checks for people starting GLP-1s. Pregnancy Medication Watch: A Danish study finds in-utero paracetamol exposure (Tylenol) may affect early reproductive development in girls, though long-term impact is still unclear. Workplace Mental Health: Finland reports the EU’s second-highest rate of work-related stress, depression or anxiety, while Denmark records the lowest—highlighting how job pressure and poor communication drive wellbeing risks. Denmark in Global Health Tech: A Denmark-led project is developing real-time water sensors to detect pesticides on site, aiming to improve public health preparedness after extreme weather. Denmark–Indonesia Dairy Push: Three Danish firms will showcase livestock and milk-analysis technology in Jakarta as Indonesia expands domestic dairy production. Policy & Access: Italy’s Meloni proposes banning burqas/niqabs in schools and capping foreign pupils per class, tying school language rules to integration.

Flu & Covid jabs at Oktoberfest: German doctors in Munich are pushing flu and Covid vaccinations for revelers as Oktoberfest crowds boost infection risk, with experts warning uptake is still too low. Real-time water pollution monitoring: A Denmark-involved project (STARDUST) is developing optical sensors to detect multiple pesticides in water on site, with citizen scientists helping collect samples after extreme weather. Niger detention deaths: Families in Niger are demanding justice after 37 men died in a crowded NSCDC holding cell; an independent panel has been appointed to investigate conditions and causes. Snakebite treatment research: New work on nanobody antivenoms aims to improve protection and reduce the batch variation and allergic reactions seen with traditional horse-made antivenom. Denmark-US Arctic security: A new US-Denmark-Greenland security agreement is framed as protecting sovereignty while deterring Russian and Chinese aggression in the Arctic. Novo & AI drug discovery: Novo Nordisk is expanding its AI push with Anthropic’s Claude to speed drug discovery, including oral cardiometabolic therapies. GLP-1 and rare eye stroke link: A UK case report raises questions after a patient on Wegovy experienced an eye stroke (NAION), prompting renewed scrutiny of risks as GLP-1 use grows.

Arctic Security Deal: The US says it has struck an “Infinite Life” agreement with Denmark and Greenland, aiming for permanent US control over Greenland security, with Denmark and Greenland expecting to sign a strengthened pact next week—raising fresh questions about sovereignty and the future of NATO-era Arctic cooperation. Workplace Pregnancy Safety: A large Danish study links frequent forward bending and more walking at work in early pregnancy to a higher miscarriage risk, adding practical guidance for employers and pregnant workers. Healthcare Innovation (Denmark-linked): Research highlights a new approach to snakebite treatment using nanobody antivenoms, aiming to improve effectiveness and reduce allergy risk compared with traditional horse-made antivenom. Mental Health & Skin Care: A real-world psoriasis study reports complete skin clearance after IL-17A inhibitor treatment is associated with lower anxiety and depressive symptoms. Public Health Research: Danish researchers also report ultrasound-guided low-level He-Ne laser therapy after acupotomy for carpal tunnel syndrome in a multicenter retrospective study. Press Freedom Clash: US President Trump bans CNN, MS NOW and Politico from the White House, escalating a fight over access and First Amendment protections. Sports & Local Impact: Denmark’s Andreas Christensen is injured in Barcelona’s match vs Sevilla, while Barcelona’s Hansi Flick praises Raphinha’s new striker role.

Arctic Security & Greenland: Trump says the US has an agreement with Denmark and Greenland for “permanent control” of security, with a joint statement saying the three sides expect to sign next week—raising fresh questions for Danish and Greenlandic oversight. Medicaid Drug Pricing: Trump announced a nationwide “GENERous” program for Medicaid drug pricing, aligning prices with countries including Denmark, but analysts warn the real savings are unclear. Drug Deals Under Scrutiny: FOI documents shared by The Washington Post describe confidential Trump-era drug-pricing deals with Pfizer and Eli Lilly, including unresolved terms and broad confidentiality. Press Freedom Clash: Trump bans CNN, MS NOW and Politico from the White House, drawing criticism over First Amendment concerns. Work & Pregnancy Health: A Danish study links frequent forward bending and more walking/standing at work in early pregnancy with higher miscarriage risk. GLP-1 Safety Signal: A UK case report describes an “eye stroke” (NAION) shortly after starting Wegovy, prompting calls for careful monitoring. Novo’s AI Push: Novo Nordisk expands its AI partnerships, including a deal with Anthropic to speed drug discovery. Psoriasis Mental Health: New real-world data links IL-17A inhibitor treatment with reduced anxiety/depressive symptoms in moderate-to-severe psoriasis.

AI + Drug Discovery: Novo Nordisk is deepening its AI push with Anthropic, using Claude models for drug discovery and biological research workflows, plus AI-driven software development at Novo. Obesity Pipeline: Novo also bought three new obesity programs from Kallyope, including a potential once-weekly non-incretin peptide candidate (K-554) aimed at regulating food intake. Cardiometabolic Deal: Danish biotech Orbis Medicines signed an up-to-$1.4bn oral cardiometabolic therapies deal with Novo, targeting injectable-to-pill transitions using AI-enabled macrocycle discovery. GLP-1 Beyond Weight: A Copenhagen-based trial suggests semaglutide may cut alcohol consumption in people with alcohol use disorder and obesity, while a separate JAMA review urges noninvasive assessment for alcohol-related liver disease and highlights liver transplant considerations for severe cases. Denmark Health Research: A Danish registry study finds paediatric/young IBD patients with ADHD or autism have similar 1-year severe disease risk, but different hospitalization patterns. Copenhagen Health Context: The World Athletics Road Running Championships kick off in Copenhagen with Team USATF’s top road-mile and 5K fields. Denmark Infrastructure for Health/Climate: INEOS and partners opened the EU’s first full-scale permanent CO₂ storage facility at Port of Esbjerg in Denmark, scaling CCS capacity for industry.

Pregnancy & Reproductive Health: A Danish study links prenatal Tylenol (acetaminophen) exposure to smaller ovaries and uteruses in daughters, raising questions about long-term reproductive outcomes and whether current pregnancy guidance should be revisited. Transplant & Respiratory Risk: New Danish data finds liver transplant recipients face worse lung function and more breathlessness than the general population, with higher rates of airflow limitation and PRISm. Cardiovascular Drug Pipeline: Novo (formerly Novo Nordisk) is partnering with Orbis Medicines on oral macrocycle cardiometabolic drugs in a deal worth up to $1.4bn, aiming to strengthen its pipeline. Short Bowel Syndrome Treatment: Zealand Pharma received a positive CHMP opinion for Zeydovio™ (glepaglutide) for adults with short bowel syndrome, with results showing reduced need for parenteral support. Mental Health & Environment: A review links air pollution exposure (including PM2.5/PM10) to higher risk of suicidal thoughts, attempts, and death. Workplace Wellbeing: An EU push calls for stronger protections for workers’ mental and physical health, including regular checks of psychosocial risks. Stroke Recovery Tech: VELA Chairs highlight a seated mobility option designed to reduce fall risk for stroke patients returning home.

Novo Nordisk/AI Drug Discovery: Danish pharma Novo is partnering with Anthropic to use Claude Science to speed up drug discovery and automate parts of clinical documentation, as it ramps up a broader AI push. Oral Biologics Deal: Novo is also backing Danish biotech Orbis Medicines in a multi-drug pact worth up to $1.4bn to develop oral “macrocycle” cardiometabolic medicines, aiming to make biologic-like effects easier to take as pills. Pregnancy Medication Safety (Denmark-linked study): A Danish study reports prenatal Tylenol exposure is associated with smaller ovarian and uterine development in daughters, while researchers stress it doesn’t prove cause and call for longer follow-up. Digital Health & Screening (UK, relevant tech): NHS England signs a £215m deal to upgrade adult screening delivery and trial AI tools, including home testing and targeted outreach for under-screened groups. Online Safety Policy (EU): The EU KIDS Act proposes a ban on social media for under-13s and supervised access rules for older children, with penalties for non-compliance. Workforce Shortage (care sector): A report highlights care workers being turned away by employers despite large vacancy numbers, pointing to staffing and access gaps.

Reproductive Health Research: A Danish study reports prenatal Tylenol (acetaminophen) exposure is linked with smaller ovarian and uterine development in daughters, raising questions about current pregnancy pain-relief guidance while researchers stress it doesn’t prove cause. Women’s Health Innovation: Hemab Therapeutics dosed the first healthy volunteer in a Phase 1 trial of HMB-003, an investigational therapy aimed at heavy menstrual bleeding by targeting clot breakdown. Cancer Care & Trials: SNIPR enrolled its first patient in Part 2 of the Phase 1b/2a SNIPR001 CRISPR phage program to prevent E. coli bloodstream infections in stem-cell transplant patients, expanding to 66 participants. Cardiometabolic Drug Pipeline: Novo (rebranded from Novo Nordisk) signed a deal worth up to $1.4B with Orbis Medicines to develop oral macrocycle therapies for cardiometabolic diseases. Public Health Policy: The EU’s proposed “EU Kids Act” would restrict social media for under-13s, allow supervised access for 13–14, and require age verification for high-risk platforms. Antibiotic Resistance Risk: A long-running MSU-led study finds livestock manure across 26 countries contains antibiotic resistance genes that could spread into water, food, and disease-causing bacteria.

AI in Drug Discovery: Danish pharma Novo (formerly Novo Nordisk) is partnering with U.S. AI firm Anthropic to use Claude Science and frontier models to speed up drug discovery and development, with Novo testing Claude on its own R&D workflows and adding human oversight and data-governance safeguards. Public Health & Climate: EU Commission President Ursula von der Leyen proposes a new European Heatwave Plan after a deadly summer, warning that rivers are drying up and care homes and hospitals overheated. Maternal Health: A Danish study reports prenatal Tylenol/acetaminophen exposure is linked with smaller ovaries and uteruses in daughters, raising questions about current pregnancy guidance and calling for longer-term follow-up. Cardiovascular Nutrition: A new analysis suggests eating four to six whole-grain servings daily lowers heart-attack and stroke risk by improving weight, blood pressure, cholesterol and blood sugar. Mental Health & ADHD: Danish research finds sex differences shape ADHD-related risks for multiple physical conditions and may affect symptoms and treatment response. Community Health: A Danish-linked waterfront group in New York is pushing for better water quality after local beach testing highlighted contamination concerns.